Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus

Published:2022-12 Issue:6 Volume:6 Page:536-551
ISSN:2542-4548
Container-title:Mayo Clinic Proceedings: Innovations, Quality & Outcomes
language:en
Short-container-title:Mayo Clinic Proceedings: Innovations, Quality & Outcomes

Author:

Wish Jay B.,Pergola Pablo

Publisher

Elsevier BV

Subject

General Medicine

Reference119 articles.

1. IDF Diabetes Atlas,2019

2. Amorim RG, Guedes GDS, Vasconcelos SML, Santos JCF. Kidney disease in diabetes mellitus: cross-linking between hyperglycemia, redox imbalance and inflammation. Arq Bras Cardiol. 2019;112(5):577-587. Published correction appears in 2019;113(1):182.

3. Inflammatory cytokines as predictive markers for early detection and progression of diabetic nephropathy;Elmarakby;EPMA J,2010

4. Central role of TGF-beta in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis;Yokoyama;Diabet Med,1996

5. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update;Am J Kidney Dis,2012

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan—A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform;Journal of Clinical Medicine;2024-08-28

2. Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease;Clinical Journal of the American Society of Nephrology;2024-07-22

3. Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials;Drug Metabolism and Pharmacokinetics;2024-06

4. The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review;Terapevticheskii arkhiv;2023-11-04

5. Novel pharmacological interventions for diabetic kidney disease;Current Opinion in Nephrology & Hypertension;2023-10-25